Panbela Therapeutics, Inc. financial data

Location
Waconia, MN
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 14 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18% % -70%
Debt-to-equity -201% % 88%
Return On Equity 305% % -90%
Return On Assets -302% % -66%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,854,831 shares -5.3%
Common Stock, Shares, Outstanding 4,854,861 shares 62%
Common Stock, Value, Issued $5,000 USD 67%
Weighted Average Number of Shares Outstanding, Basic 4,854,861 shares 3232%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $24,704,000 USD 38%
General and Administrative Expense $4,354,000 USD -25%
Operating Income (Loss) $29,058,000 USD -22%
Nonoperating Income (Expense) $983,000 USD 1265%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $28,075,000 USD -19%
Income Tax Expense (Benefit) $158,000 USD 12%
Net Income (Loss) Attributable to Parent $27,913,000 USD -19%
Earnings Per Share, Basic 284 USD/shares 97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $142,000 USD -84%
Assets, Current $5,168,000 USD 174%
Other Assets, Noncurrent $0 USD -100%
Assets $5,168,000 USD -51%
Accounts Payable, Current $10,950,000 USD 66%
Accrued Liabilities, Current $5,469,000 USD 383%
Liabilities, Current $20,142,000 USD 126%
Liabilities $23,336,000 USD 78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $541,000 USD -61%
Retained Earnings (Accumulated Deficit) $146,936,000 USD -5.1%
Stockholders' Equity Attributable to Parent $18,168,000 USD -632%
Liabilities and Equity $5,168,000 USD -51%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,392,000 USD 3.7%
Net Cash Provided by (Used in) Financing Activities $7,082,000 USD -48%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 4,854,931 shares 62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,316,000 USD -159%
Interest Paid, Excluding Capitalized Interest, Operating Activities $266,000 USD -31%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $28,748,000 USD -22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $128,223,000 USD 21%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $103,000 USD -43%
Interest Expense $278,000 USD -28%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%